跳至主要内容
临床试验/EUCTR2018-000752-18-NL
EUCTR2018-000752-18-NL进行中(未招募)1 期

Ajmaline provocation in asymptomatic PLN and PKP2 mutation carriers for early detection of Arrhythmogenic Cardiomyopathy - Ajmaline provocation in ACM

MC Utrecht0 个研究点目标入组 72 人开始时间: 2019年2月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Age =18 years
  • Pathogenic PLN mutation, pathogenic PKP2 mutation or patients without structural heart disease who are referred for ajmaline provocation to exclude Brugada syndrome.
  • Referral for cardiac MRI during routine clinical practice
  • New York Heart Association functional class = 1.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 12

排除标准

  • Severe hepatic impairment (Child-Pugh class C)
  • Severe renal dysfunction (eGFR <30 ml/min/kg)
  • Symptomatic heart failure, NYHA = 2
  • Women who are currently pregnant
  • Known intolerance or contraindication to Ajmaline
  • Sick sinus syndrome, second or third degree AV block
  • Recent myocardial infarction
  • Known strong allergic reaction to ECG electrodes

研究者

发起方
MC Utrecht

相似试验